Search hospitals > Texas > Fort Worth
Texas Oncology-Fort Worth Cancer Center
Claim this profileFort Worth, Texas 76104
Global Leader in Cancer
Global Leader in Ovarian Cancer
Conducts research for Breast Cancer
Conducts research for Ovarian Tumors
Conducts research for Lung Cancer
98 reported clinical trials
5 medical researchers
Summary
Texas Oncology-Fort Worth Cancer Center is a medical facility located in Fort Worth, Texas. This center is recognized for care of Cancer, Ovarian Cancer, Breast Cancer, Ovarian Tumors, Lung Cancer and other specialties. Texas Oncology-Fort Worth Cancer Center is involved with conducting 98 clinical trials across 103 conditions. There are 5 research doctors associated with this hospital, such as Noelle Cloven, MD, Stephen Richey, Chi M Pham, and Harris Naina, MD.Area of expertise
1Cancer
Global LeaderStage III
Stage IV
BRCA2 positive
2Ovarian Cancer
Global LeaderStage IV
BRCA1 positive
BRCA2 positive
Top PIs
Noelle Cloven, MDTexas Oncology-Fort Worth Cancer Center4 years of reported clinical research
Expert in Ovarian Cancer
Studies Ovarian Tumors
21 reported clinical trials
39 drugs studied
Stephen RicheyTexas Oncology - Fort Worth5 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Colorectal Cancer
8 reported clinical trials
17 drugs studied
Chi M PhamUSO - Texas Oncology3 years of reported clinical research
Studies Breast Cancer
Studies Cancer
3 reported clinical trials
9 drugs studied
Harris Naina, MDTexas Oncology - Fort Worth3 years of reported clinical research
Studies Lymphoma
Studies B-Cell Lymphoma
3 reported clinical trials
14 drugs studied
Clinical Trials running at Texas Oncology-Fort Worth Cancer Center
Breast Cancer
Ovarian Cancer
Prostate Cancer
Endometrial Cancer
Cancer
Ovarian Tumors
Pancreatic Cancer
Tumors
Bladder Cancer
Lymphoma
Imlunestrant + Abemaciclib
for Breast Cancer
This study is evaluating whether a drug called LY3484356 can help treat breast cancer.
Recruiting2 awards Phase 39 criteria
Giredestrant + Hormone Therapy
for Early-Stage Breast Cancer
This study is evaluating whether a drug called giredestrant can improve the survival of women with early breast cancer.
Recruiting2 awards Phase 311 criteria
NUV-868 + Olaparib/Enzalutamide
for Cancer
NUV-868-01 is a first-in human, open- label, Phase 1/2 dose escalation and expansion study in patients with advanced solid tumors. The Phase 1 and 1b portions include patients with advanced solid tumors and are designed to determine the safety and the dose(s) of NUV-868 to be used as monotherapy and in combination with olaparib or enzalutamide for the Phase 2 portion. In Phase 2, NUV-868 in combination with olaparib or enzalutamide will be given to determine the safety and efficacy of these study treatments. One cohort of patients (with enzalutamide-naïve metastatic castration-resistant prostate cancer) will be randomized to receive either NUV-868 monotherapy, enzalutamide monotherapy, or the combination of NUV-868 + enzalutamide. Patients will self-administer NUV-868 orally daily in 28-day cycles as monotherapy in Phases 1 and 2. In Phases 1b and 2, patients will self-administer NUV-868 orally daily in 28-day cycles in combination with olaparib or enzalutamide daily at standard prescribed doses (Phase 1b) or at the recommended Phase 2 combination dose (RP2cD) that is determined in Phase 1b. Patients will be treated until disease progression, toxicity, withdrawal of consent, or termination of the study.
Recruiting1 award Phase 1 & 211 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Texas Oncology-Fort Worth Cancer Center?
Texas Oncology-Fort Worth Cancer Center is a medical facility located in Fort Worth, Texas. This center is recognized for care of Cancer, Ovarian Cancer, Breast Cancer, Ovarian Tumors, Lung Cancer and other specialties. Texas Oncology-Fort Worth Cancer Center is involved with conducting 98 clinical trials across 103 conditions. There are 5 research doctors associated with this hospital, such as Noelle Cloven, MD, Stephen Richey, Chi M Pham, and Harris Naina, MD.